2021
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
Fudim M, Zhong L, Patel KV, Khera R, Abdelmalek MF, Diehl AM, McGarrah RW, Molinger J, Moylan CA, Rao VN, Wegermann K, Neeland IJ, Halm EA, Das SR, Pandey A. Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. Journal Of The American Heart Association 2021, 10: e021654. PMID: 34755544, PMCID: PMC8751938, DOI: 10.1161/jaha.121.021654.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHeart FailureHumansMedicareNon-alcoholic Fatty Liver DiseaseRetrospective StudiesRisk FactorsStroke VolumeUnited StatesConceptsNonalcoholic fatty liver diseaseIncident heart failureReduced ejection fractionFatty liver diseaseHeart failureEjection fractionMedicare beneficiariesHF subtypesLiver diseaseHigh riskBackground Nonalcoholic fatty liver diseaseBaseline NAFLDAssociation of NAFLDNew-onset heart failureConclusions PatientsCohort studyPrior diagnosisBlack patientsNinth RevisionKidney diseaseOutpatient claimsRisk factorsIndependent associationHigh burdenMedicare patients
2015
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis
Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis. Hepatology 2015, 62: 1417-1432. PMID: 26189925, DOI: 10.1002/hep.27999.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsChenodeoxycholic AcidDrug Therapy, CombinationHumansNon-alcoholic Fatty Liver DiseasePioglitazonePublication BiasRosiglitazoneThiazolidinedionesVitamin EConceptsModerate-quality evidenceNonalcoholic steatohepatitisObeticholic acidLobular inflammationBallooning degenerationVitamin ERelative riskComparative effectivenessBiopsy-proven nonalcoholic steatohepatitisLow-quality evidenceUse of pentoxifyllineIndirect treatment comparisonFuture comparative trialsHigh-quality evidenceConfidence intervalsQuality of evidenceDistinct histological featuresRecommendations AssessmentSecondary outcomesPrimary outcomeCombination therapyFibrosis stageHistological featuresComparative trialsPharmacological interventions